Onward Medical announced today that it received a grant to study its ARC-BCI therapy to restore upper limb movement after subcortical stroke. The Eindhoven, The Netherlands-based company received the grant from the European Innovation Council (EIC). It can now study the investigational brain-computer interface previously designed to restore lower limb mobility after spinal cord injury […]
Onward Medical
Ottobock becomes Onward Medical’s largest shareholder
Ottobock recently announced that it has invested €22.5 million in spinal cord stimulation tech developer Onward Medical. The investment, announced Oct. 24, makes Ottoback (Duderstadt Germany) the largest shareholder in Onward Medical (Eindhoven, The Netherlands). Ottobock’s board chair and owner Hans Georg Näder said: “As the innovation leader in our industry, we see great potential in […]
Former Medtronic president to become board chair at Onward Medical
Onward Medical announced today that it appointed long-time Medtronic executive Rob ten Hoedt as the new chair of its board of directors. The Eindhoven, The Netherlands-based spinal cord stimulation technology developer plans for ten Hoedt to become chair at year-end. This follows the planned retirement of Jan Ohrstrom, current director and chair, after eight years. […]
Onward licenses BCI technology from CEA
Onward Medical announced today that it signed an exclusive license with CEA to develop and commercialize brain-computer interface (BCI) technology. The license enables Onward to develop and commercialize the investigational WImagine BCI interface designed by CEA. It comes as part of the company’s investigational ARC-BCI system for restoring lower limb mobility after spinal cord injury […]
Onward reports third brain-computer interface implant
Onward Medical today announced the third successful implant of its ARC-BCI brain-computer interface offering to restore mobility. Eindhoven, the Netherlands–based Onward designed ARC-BCI to restore lower limb mobility after spinal cord injury (SCI). The BCI offering combines the ARC-IM stimulator implant with the WImagine BCI from CEA-Clinatec. Onward reported the first human implant of the […]
Onward receives $1.1M Christopher & Dana Reeve Foundation grant to expand BCI study
Onward Medical announced today that it received a grant from the Christopher & Dana Reeve Foundation to support an ongoing study. The $1.1 million grant supports the expansion of an ongoing early clinical feasibility study of the use of the company’s brain-computer interface (BCI). Onward’s study evaluates the use of BCI to restore thought-driven use […]
Another 5 brain-computer interface companies you should know
Over the past several months, there have been a number of significant developments in the brain-computer interface (BCI) space. The likes of Neuralink, Synchron and Precision Neuroscience, among others, continue to advance their platforms. Some even began clinical trials, while many more companies are vying to be the first to bring a BCI to market. […]
Onward ARC-EX nerve stim hits pivotal trial endpoints, restores limb function
Onward Medical announced positive data supporting the use of its ARC-EX nerve stimulation therapy for restoring upper limb movement. The Netherlands-based company published findings from the Up-LIFT pivotal trial in Nature Medicine. Up-LIFT achieved all primary safety and effectiveness endpoints. Additionally, ARC-EX showed significant improvements in upper limb strength, function and sensation among those with chronic […]
Onward submits movement-restoring spinal cord stim tech to FDA
Onward Medical announced today that it submitted a de novo application to the FDA for the approval of its ARC-EX spinal cord stimulation system. The Eindhoven, the Netherlands-based company designed ARC-EX to restore function of upper extremities after spinal cord injury (SCI). If approved, the company says ARC-EX would become the first ever SCS therapy […]
Onward raises $22M to support neurostim tech
Onward Medical announced today that it successfully raised $21.8 million (€20 million) in gross proceeds through a private placement. The company offered more than 4.4 million new ordinary shares at an issue price of $4.89 (€4.50) per share. It completed the offering with participation from institutional investors, certain founders and management and members of the […]
FDA accepts Onward BCI into advisory program
Onward Medical announced today that the FDA accepted it into its new Total Product Lifecycle Advisory Program (TAP) — a move that could boost the development of Onward’s BCI technology. Acceptance into the TAP program comes on the heels of FDA breakthrough device designation for the ARC-BCI system last month. Breakthrough device designation is a […]
